Business Wire

MI-HARMAN

14.9.2022 15:27:35 CEST | Business Wire | Press release

Share
Introducing HARMAN Ready Care: Detects Driver Behaviors and Assists via Context-Aware Interventions for Safer and Smarter Drives

HARMAN International, a wholly-owned subsidiary of Samsung Electronics Co., Ltd. focused on connected technologies and solutions for automotive, consumer and enterprise markets, today announced the introduction of Ready Care — the latest solution in its expanding portfolio of products designed and built to deliver consumer-focused experiences at an automotive grade. Ready Care is a set of solutions — Cognitive Distraction, Stress-Free Routing, and Personalized Comfort — that can work together or independently to improve safety and reduce driver stress.

Ready Care delivers heightened levels of safety and wellbeing through the integration of several key technologies. In addition to employing cameras that can detect driver drowsiness, Ready Care measures real-time driver cognitive load to identify when potential distractions arise, and then offers tailored intervention strategies to maximize safety. The experience is powered by newly developed machine learning algorithms, which gather and process data from in-vehicle cameras and sensors to monitor a driver’s state. Ready Care can then generate customized in-vehicle cabin prompts to trigger a range of behavioral responses — increasing awareness, alleviating stress, or stimulating relief.

“Safety remains a top concern for consumers when considering a new vehicle purchase, and now, with Ready Care, OEMs can improve vehicle safety in a significant new way,” said Armin Prommersberger, Senior Vice President, Automotive Product Management at HARMAN International. “Ready Care is essentially a co-pilot, spotting when distractions could turn into dangerous situations and intervening to avoid them. For the first time, the vehicle can, in a sense, know what the driver is thinking; this is a game changer. We are incredibly proud of and excited by the impact Ready Care will have for drivers, passengers, and everyone on the road.”

Key features of Ready Care include:

  • Eyes and Mind on Road: Ready Care measures both driver eye activity and state of mind. An infra-red global shutter camera with active illumination surveys the driver’s face in low and high light environments to provide real-time data into facial expressions, eye gaze, eyelid openings, and more. The HARMAN Cognitive Distraction feature — a real-time driver visual and cognitive load measurement tool — deciphers when the driver is mentally distracted and can initiate multiple and simultaneous in-cabin vehicle intervention responses. It measures real-time driver cognitive load and separates driving tasks from other mental activities as well as visual and manual distractions to enable tailored intervention strategies that maximize safety.
  • Stress-free Routing: Compatible with multiple navigation engines, Ready Care provides an alternate route selection to lower elevated driver stress levels while on the road. Through detecting real-time stress factors like traffic jams or weather and adapting accordingly, this solution helps mitigate the driver’s state of stress or anxiety.
  • Personalized Experiences: As all journeys and drivers are unique, Ready Care leverages advanced machine learning technology to provide personalized intervention strategies tailored to the individual and their driving experience. Ready Care delivers closed-loop interventions via an SDK, allowing OEMs and third parties to integrate any vehicle feature or function — such as HVAC control, media content and volume, or seat sensors — into the Ready Care solution. An example could be the advanced technologies offered by Gentherm, the global market leader of innovative thermal management and pneumatic comfort technologies for the automotive industry.

Ready Care equips OEMs with advanced but meaningful technology to improve driver safety and wellbeing. Automotive manufacturers have the opportunity to incorporate the full set of Ready Care solutions into vehicles or choose specific features to create a more customized solution right for their customers and fleets.

For decades, HARMAN has been uniquely positioned at the intersection of automotive and consumer technology innovation, resulting in meaningful, industry-leading solutions. Through its key consumer and technology brands, deep industry expertise, and robust technology stack, HARMAN is equipped to deliver on the promise of consumer experiences through automotive-grade solutions today.

For more information on HARMAN’s Ready Care solution, visit car.harman.com/experiences/ready-care.

About HARMAN

HARMAN (harman.com) designs and engineers connected products and solutions for automakers, consumers, and enterprises worldwide, including connected car systems, audio and visual products, enterprise automation solutions; and services supporting the Internet of Things. With leading brands including AKG®, Harman Kardon®, Infinity®, JBL®, Lexicon®, Mark Levinson® and Revel®, HARMAN is admired by audiophiles, musicians and the entertainment venues where they perform around the world. More than 50 million automobiles on the road today are equipped with HARMAN audio and connected car systems. Our software services power billions of mobile devices and systems that are connected, integrated and secure across all platforms, from work and home to car and mobile. HARMAN has a workforce of approximately 30,000 people across the Americas, Europe, and Asia. In 2017, HARMAN became a wholly-owned subsidiary of Samsung Electronics Co., Ltd.

© 2022 HARMAN International Industries, Incorporated. All rights reserved. Harman Kardon, Infinity, JBL, Lexicon and Mark Levinson are trademarks of HARMAN International Industries, Incorporated, registered in the United States and/or other countries. AKG is a trademark of AKG Acoustics GmbH, registered in the United States and/or other countries. Features, specifications, and appearance are subject to change without notice.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220914005609/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release

Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he

Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release

Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release

Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release

The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye